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Abstract
Background: Tau protein is the principal component of the neurofibrillary tangles found in Alzheimer’s disease,
where it is hyperphosphorylated on serine and threonine residues, and recently phosphotyrosine has been
demonstrated. The Src-family kinase Fyn has been linked circumstantially to the pathology of Alzheimer’s disease,
and shown to phosphorylate Tyr18. Recently another Src-family kinase, Lck, has been identified as a genetic risk
factor for this disease.
Results: In this study we show that Lck is a tau kinase. In vitro, comparison of Lck and Fyn showed that while both
kinases phosphorylated Tyr18 preferentially, Lck phosphorylated other tyrosines somewhat better than Fyn. In
co-transfected COS-7 cells, mutating any one of the five tyrosines in tau to phenylalanine reduced the apparent
level of tau tyrosine phosphorylation to 25-40% of that given by wild-type tau. Consistent with this, tau mutants
with only one remaining tyrosine gave poor phosphorylation; however, Tyr18 was phosphorylated better than the
others.
Conclusions: Fyn and Lck have subtle differences in their properties as tau kinases, and the phosphorylation of tau
is one mechanism by which the genetic risk associated with Lck might be expressed pathogenically.
Background
The microtubule-associated protein tau is the main
component of paired helical filaments (PHF) which are
aggregated structures found in neurofibrillary tangles
(NFT) in the brains of patients with Alzheimer’sd i s e a s e
(AD). Neurofibrillary tangles are found in a number of
other diseases termed ‘tauopathies’ which include fron-
totemporal dementia with Parkinsonism linked to chro-
mosome 17 (FTDP-17), Pick’s disease, progressive
supranuclear palsy and corticobasal degeneration. The
presence of tau deposits in all of these neurodegenera-
tive diseases and particularly in FTDP-17, whose
patients have mutations in the tau gene itself [1], sug-
gests that tau protein may have an important role in the
neurodegenerative process.
The tau in PHF (PHF-tau) is phosphorylated on over
40 serine and threonine residues [2-5] and this
hyperphosphorylation hinders the ability of tau to bind to
microtubules [6] and to promote microtubule assembly
[7]. Several candidate kinases have been identified that
can phosphorylate tau in vitro, including glycogen
synthase kinase 3b (GSK-3b) [8,9]. GSK-3b can phos-
phorylate tau in cells, and inhibition of GSK-3b using
lithium leads to a reduction in the degree of tau phos-
phorylation in neurons [10-13], which implies that GSK-
3b is a physiological tau kinase.
The hyperphosphorylation of serines and threonines in
PHF-tau is well documented, as is the lower level of
phosphorylation in tau extracted from healthy adult or
foetal brain [2,14,15]. However there is now evidence
that phosphorylation of tyrosine residues in tau also
occurs. We have shown that PHF-tau preparations from
some AD cases contain tyrosine-phosphorylated tau
[16,17], and Ab peptide treatment of cultured neurons
induced tyrosine phosphorylation of several proteins
including tau [16]. Of the five tyrosine residues in
human tau (Figure 1), phosphorylation of Tyr197 [18]
and of Tyr394 [17] have been identified in PHF-tau, and
of Tyr394 in foetal tau [17] using mass spectrometry.
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dies, to be phosphorylated in foetal and degenerating
brain and in PHF, but not in healthy adult brain [19]. In
tau-transfected fibroblasts and in SH-SY5Y human neu-
roblastoma cells the generic tyrosine phosphatase inhibi-
tor, vanadate induced the phosphorylation of transfected
tau primarily on Tyr394 [17]. Co-transfection of cells
with tau kinases showed that Fyn and Syk phosphory-
lated tau principally on Tyr18, but Abl replicated the
endogenous kinase activity by phosphorylating tau prin-
cipally on Tyr394 [17,20]. Furthermore, in the JNPL3
mouse model of tauopathies which carries the tau
P301L mutation, tyrosine phosphorylation at Tyr197
and Tyr394 was identified which increased with age and
correlated with the formation of tau aggregates [18].
The Src family kinases, of which Fyn and Lck are
members, are tyrosine kinases related to Src which was
first identified as a viral protein (v-Src) in Rous sarcoma
virus [21,22]. Src family kinases are characterised by six
functional domains: the Src homology (SH) 4 domain; a
unique region to each kinase; the SH3 domain; the SH2
domain; the catalytic domain and a negative regulatory
C-terminal tail [23]. The family members Src, Fyn, Lck,
Lyn and Yes are expressed in the CNS [24-29]. Initial
evidence for the role of Src family kinases in AD was
the discovery that a subset of neurons in AD brain show
intense Fyn labelling compared to neurons in healthy
brain [25]. Increased Fyn immunoreactivity has been
shown in transgenic AD model mice [30]. Conversely,
cognitive impairments were found in transgenic AD
model mice overexpressing Fyn [31], and an increased
level of Fyn in AD brains was correlated with cognitive
impairment [32]. Brain slices and primary cortical neu-
ronal cultures from Fyn knockout mice are resistant to
the neurotoxic effects of amyloid-b oligomers [33,34],
further implicating Src-family kinases in AD pathogen-
esis. Fyn is able to activate GSK-3b, which raises the
possibility of Fyn being involved in the mechanism
which leads to the serine and threonine hyperphosphor-
ylation seen in AD [35]. Significant evidence, therefore,
suggests a role for Fyn in AD. The Src family kinase
member Lck, which is also present in neurons [26,27],
has been reported to be down-regulated in AD [36], and
interestingly the Lck gene locus has been reported to
contain a risk factor for AD [37] located in Intron
1. This suggests that Lck may also play a role in the
development of AD in affected individuals and this may
be protective. The functional importance of the expres-
sion of Lck in neurons has also been demonstrated in
Lck deficient mice where lack of Lck in retinal neurons
causes development abnormalities in retinal architecture
[38].
To address the issue of the role of Lck in AD, we
investigated the phosphorylation of tau by Lck. Whilst
Fyn and Lck had overlapping in vitro activity profiles,
two main differences were found: (i) two-dimensional
phosphopeptide maps and mass spetrometry revealed
that Lck was somewhat better than Fyn at phosphorylat-
ing tyrosines other than Tyr18; and (ii) in co-transfected
fibroblasts, mutation of tyrosines to phenylalanines
interfered with phosphorylation by Lck of the remaining
tyrosines. The in vivo activity profile of Lck contrasted
with our previously reported findings where only the
mutation of Tyr18 gave a marked reduction of phos-
phorylation in co-transfection experiments with Fyn.
Together these differences suggest that Lck may interact
with tau in a way that is subtly different from Fyn, with
the possibility of a different role in generating pathology
in AD.
Results
Analysis of tau phosphopeptides after in vitro
phosphorylation
Phosphorylation of recombinant 2N4R tau in vitro by
recombinant Lck or Fyn gave a stoichiometry of
approximately 0.3 phosphates per mol of tau. This level
of phosphorylation was expected to be adequate for site
identification by mass spectrometry, while not being so
high as to force the phosphorylation of non-physiologi-
cal sites.
Tau phosphorylated in vitro using either recombinant
Lck or Fyn was isolated by gel electrophoresis, and after
trypsin digestion, the peptides were analysed by
MALDI-ToF MS and LC-MS/MS. Phosphorylated pep-
tides were identified by an increase of 80 Da in the
mass of the peptide, and the location of the phosphate
was confirmed in the second MS phase from sequence
information given by collision-induced fragmentation.
Figure 1 Isoforms of tau and tau constructs used. The shortest
isoform (0N3R) lacks two N-terminal exons (shown in pale grey in
2N4R) and the second of the microtubule binding repeats (dark grey)
due to alternative splicing. Tau-NT and Tau-CT represent the N-terminal
and C-terminal halves of 0N4R tau. The numbering of residues in all
constructs used is that of the 2N4R isoform of human tau.
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fied as containing phosphotyrosine residues in tau
phosphorylated by Lck or Fyn. For a typical phospho-
peptide analysis see additional File 2: Figure S1 and
additional File 3: Table S2. For both Lck-phosphory-
lated and Fyn-phosphorylated tau, phosphopeptides
containing each of the five tyrosines were found (tyro-
sines 18, 29, 197, 310 and 394). The positions of the
phosphates were positively identified from the frag-
mentation patterns in the majority of cases, but in sev-
eral cases ions in the MS survey scan did not meet the
switching criteria to obtain MS/MS fragmentation
data. Visual inspection of the MS survey scan allowed
identification of the phosphorylated peptide by either
comparison of the m/z and retention time of the ion
with that of the corresponding phosphopeptide for
which sequence information had been assigned (e.g.
Fyn, Tyr394), or, in the case of Tyr29 by extraction of
the ion at the m/z of the unphosphorylated peptide
from both Fyn-phosphorylated and Lck-phosphorlyated
tau which had been sequenced by MS/MS. The ion at
m/z corresponding to the phosphorylated peptide was
then extracted and a putative identification given if the
retention time and charge state was equivalent to its
unphosphorylated counterpart. The ratio of phosphory-
lated peptides to their non-phosphorylated equivalents
suggested that the amount of phosphorylation of each
residue was generally somewhat greater with the Lck
preparation used than with Fyn.
Two-dimensional phosphopeptide mapping of tau
The LC-MS/MS data from Lck-phosphorylated and Fyn-
phosphorylated tau were clearly similar. However, the
sequence identification of phosphopeptides was incom-
plete and, to overcome the intrinsically non-quantitative
nature of this technique, 2D phosphopeptide mapping
was also used. Maps of tau peptides from Lck and Fyn
phosphorylation are shown in Figure 2A and 2B, respec-
tively. Eight spots generated by Lck (see Figure 2A)
were analysed for phosphoamino acid content (exempli-
fied in Figure 2C) and all eight were found to contain
only phosphotyrosine. Although the 2D maps generated
by Lck and Fyn had similar overlapping patterns, there
were two additional spots generated by Lck (Figure 2A,
bold arrows), one of which (labelled b) was shown che-
mically to contain phosphotyrosine, and one additional
minor spot generated by Fyn (Figure 2B arrowhead).
Their possible identities are considered later in this
section.
In order to identify the phosphopeptides in the 2D
spots, the cellulose layer containing the spots was
scraped off, extracted, and analysed by mass spectrome-
try. Those spots where a phosphopeptide was success-
fully identified are indicated by numbers in Figure 2A
and Figure 2B, and the identifications are shown in addi-
tional File 4: Table S3. Remarkably, spots 1-4 were all
found to contain pTyr18. The three spots identified in
Fyn-phosphorylated tau (1f, 2f and 3f) all contained the
same similarly-migrating peptides produced by Lck (1, 2
and 3). It should be noted that, although not identified,
from its position the spot to the right of the arrow-
headed spot in Figure 2B is suspected to be equivalent
to spot 4 on the Lck generated map (Figure 2A) and
therefore also to contain Tyr18. None of the apparently
unique peptides produced by Lck or Fyn (arrows and
arrowhead) could be identified by mass-spectrometry.
Control maps (not shown) with kinase but without tau
did not produce spots, so those spots are likely to have
originated from tau rather than from proteins in the
kinase preparations.
Figure 2 2D Phosphopeptide mapping of tau phosphorylated
by Lck or Fyn. The origin of the samples is marked (X). A, Map of
2N4R tau phosphorylated by Lck. B, Map of 2N4R tau
phosphorylated by Fyn. Arrowhead and bold arrows indicate
phosphopeptide spots apparently unique to tau phosphorylated by
Fyn and by Lck respectively. Numbered spots contained
phosphopeptides which were identified by mass spectrometry (see
additional File 4: Table S3). Spots 1, 2, 3, 4, 1f, 2f, and 3f were
identified by matching the peptide masses measured by MALDI-ToF
MS with the theoretical masses of peptides. Also, peptides and
phosphotyrosines in spots 1, 2, 3, 4, 5 and 3f were identified by
direct sequencing by MS/MS. Peptides in spots a, b and c were not
identified by mass spectrometry. C, Phosphoamino acid analysis: a
representative phosphoamino acid analysis as performed on eight
of the Lck-generated phosphopeptide spots, where the circles show
the outlines of the ninhydrin-positive phosphoamino acid standards.
Spots thus analysed included 1, 3, 4 and 5, and those labelled a, b
and c in Figure 3A, and all were found to contain only
phosphotyrosine; a further phosphotyrosine-containing spot ran
above spot 1 and so is not seen in 2A.
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was shown by LC-MS/MS sequencing to contain
pTyr197. Thus, although Tyr197 was inferred only from
the MS survey scan in the peptide mixture (see addi-
tional File 1: Table S1), analysis of this peptide spot
clearly showed that Lck does phosphorylate this tyrosine
residue. Longer exposure of 2D maps from Fyn-
phosphorylated tau also demonstrated a radiolabelled
phosphopeptide in this position (data not shown).
To further confirm the identity of spots, tau fragments
containing only the N-terminal half of 0N tau (Tau-NT)
or the C-terminal half of 4R tau (Tau-CT) (see Figure 1)
were phosphorylated by Lck and the phosphopeptides
were mapped (see additional File 5: Figure S2, A and B).
The three main spots found from Tau-CT (arrowed)
can be attributed to Tyr310 and Tyr394, and a mixing
experiment (see additional File 5: Figure S2, C and D)
shows their positions more clearly in relation to the
other (i.e. NT-derived) peptides.
0N3R tau (the smallest CNS tau isoform) also contains
all five tyrosines, and its 2D phosphopeptide map was
very similar to that of 2N4R tau (not shown). However,
due to its proximity to a splice junction, the phospho-
peptide containing Tyr310w o u l dh a v ead i f f e r e n t
N-terminal portion for the two isoforms. One relatively
hydrophobic peptide (the uppermost arrowed spot in
F i g u r eS 2 ,A ,Ca n dDa n dl a b e l l e d“a” in Figure 2A)
was found in a different position in maps from the two
isoforms. This spot therefore is likely to contain Tyr310
and suggests that the other spots present on the Tau-
CT map, which includes the two arrowed spots in
Figure 2A that were unique to the Lck generated map,
are likely to contain Tyr394.
From a combination of these data the identity of many
of the phosphopeptides can be deduced, shown in Figure
3., although one spot remained unidentified (labelled “c”
in Figure 2A and left unlabelled in Figure 3). Although the
results are self-consistent, spots may contain more than
one peptide and so the possibility exists that the identifica-
tions by mass spectrometry may not be complete.
In the 2D phosphopeptide maps (Figures 2 and 3, and
for peptide identity see additional File 4: Table S3) four
prominent spots were each identified as containing
pTyr18. This multiplicity was due to alternative trypsin
cleavage sites around a consecutive pair of basic
residues, and to the oxidation of methionine. Phosphor-
ylation by Lck of the N-terminal fragment of tau
(Tau-NT), which contains tyrosines 18, 29 and 197,
incorporated much more radioactivity than phosphoryla-
tion of Tau-CT, even though no pTyr29 phosphorylation
was detected and Tyr197 appears to be a minor site. This
also suggests that Tyr18 is the major site phosphorylated
by Lck. These results are consistent with the earlier
results from transfection studies using Fyn [17].
Clearly, Lck and Fyn showed very similar phosphoryla-
tion patterns (Figure 2), with Tyr18 as the main site.
The two unidentified peptides that appeared unique to
Lck (Figure 2A, arrowed) migrated close to the peptides
suggested to contain pTyr394. If they are indeed these
pTyr394-containing peptides, this would suggest that
Lck may phosphorylate Tyr394 rather better than Fyn
does, but this requires confirmation. The greater radio-
activity in Spot 5 with Lck (Figure 2A), compared to the
equivalent one with Fyn (Figure 2B) which needed a
longer exposure (described above), suggests that Tyr197
is a better site for Lck than for Fyn. The minor tau
phosphopeptide that is apparently unique to Fyn was
not identified (Figure 2B, arrowhead). Positions of spots
on 2D maps provided confirmatory evidence for the
identification of some of the phosphopeptides.
In summary; four of the five tyrosines in tau were
positively identified as Lck phosphorylation sites, and
two as Fyn sites (summarised in Table 1). The phospho-
peptide containing the fifth tyrosine, Tyr29 (residues
2 4 - 4 4 )w a si d e n t i f i e do n l yf r o mi t sm a s sa n dm a s s -
difference on dephosphorylation; therefore the possibi-
lity that the phosphate was on Thr30 or Thr39 rather
than on Tyr29 cannot be completely disregarded.
Phosphorylation of tau by Lck in co-transfected cells
In order to determine if the phosphorylation of tau by
Lck seen in vitro could also take place in cells, co-
transfection experiments were undertaken. Western
blotting with the phosphotyrosine specific antibody
4G10 revealed bands of tyrosine-phosphorylated pro-
teins at approx. 68 kDa (Figure 4A, top panel), which
co-migrated with the tau bands in the second panel.
Figure 3 Summary of phosphopeptide spot identification.
Underlined labels denote the phosphotyrosines in peptides
identified in spots by a combination of MALDI-ToF MS and LC-MS/
MS mass spectrometry. Italics show tentative identification of
phosphotyrosines in spots by other methods. Unlabelled spots were
not identified.
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lity shifts resulting from phosphorylation on serines and
threonines as well as tyrosine.
In order to identify which tyrosine or tyrosine residues
were phosphorylated, tau constructs were used where
each had one tyrosine converted to phenylalanine.
A construct was also used, designated YAllF, where all
five tyrosines had been converted to phenylalanine,
which showed no detectable tyrosine-phosphorylated tau
(Figure 4A). Replacement of any one tyrosine gave sub-
stantial reduction in tyrosine phosphorylation by Lck,
but a basal level of phosphorylation was still detectable.
This is in marked contrast to results with Fyn and Abl,
where deletion of Y18 and Y394 ablated phosphorylation
by Fyn and Abl respectively [17,20]. This suggests that
multiple tyrosines can be phosphorylated simulta-
neously. Calculations from three experiments (Figure
4B) showed that mutation of any one tyrosine reduced
the phosphorylation to 25-40% of that given by wild-
type tau. This suggests therefore that the interaction of
Lck with tau is disproportionately abrogated by removal
of any one of the five tyrosine hydroxyl groups.
An alternative approach is to use tau containing only
one tyrosine, the other four having been converted to
phenylalanine [17], and compare these as substrates for
phosphorylation. In view of the marked reduction seen
by replacement of any one tyrosine (Figure 4, A and B),
we anticipated that replacement of four would allow
very little phosphorylation. Indeed, we could not detect
any phosphorylation by wild-type Lck when it was co-
transfected with any of the tau constructs with a single
tyrosine remaining (results not shown). Therefore we
repeated the experiment with an activated Lck mutant,
LckY505F, where the inhibitory tyrosine phosphorylation
site near the C-terminus, characteristic of Src-family
kinases, had been mutated to phenylalanine. In tau that
had only Tyr18 remaining there was a strongly
Table 1 Identification of phosphorylated tyrosines in tau
by mass spectrometry after phosphorylation by Lck and
Fyn
Phosphorylated
Residue
Lck Fyn
LC-MS/MS
a2D-MS/MS LC-MS/MS
a2D-MS/MS
Tyr18 + + + +
Tyr29 (ss) - (ss) -
Tyr197 (ss) + (ss) -
Tyr310 + - (ss) -
Tyr394 + - + -
+, site positively identified by MS/MS.
(ss), survey scan (first MS spectrum) or MALDI-ToF MS; phosphopeptides
identified by mass and mass-difference (phosphate loss) only.
a LC-MS/MS analyses on phosphopeptides extracted from radiolabelled spots
on 2D maps.
Figure 4 Phosphorylation of tau by Lck in co-transfected
COS-7 cells. DNA constructs coding for V5-tagged tau 2N4R and
for Lck were co-transfected into COS-7 cells. In A and B the tyrosine
phosphorylation given by wild-type Lck of tau with single
replacements of tyrosines is shown, while in C the phosphorylation
by activated Lck (LckY505F) of tau with single tyrosines remaining is
shown. Lysates were immunoprecipitated with anti-V5 antibody and
Western blots were probed with 4G10 antiphosphotyrosine
antibody (A top panel, and C) and with anti-tau antibody (A, middle
panel), showing approximately equal immunoprecipitation of each
tau construct; probing of lysates with anti-Lck antibody (A, bottom
panel) showed that approximately equal amounts of Lck were
expressed with each tau construct, although Lck alone gave
stronger expression. B shows the amounts of immunoprecipitated
tau phosphotyrosine after normalisation against immunoprecipitated
tau (means of 3 experiments, +/- SEM). WT, wild-type tau (with all
5 tyrosines); YAllF, tau with all five tyrosines replaced by
phenylalanines. In A and B, tau with single replacements of a
tyrosine with phenylalanine are designated Y18F, Y29F, etc, and in C
the mutants with a single tyrosine remaining are designated Y18R,
Y29R, etc.
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phorylated as wild-type tau (Figure 4C). Results for the
other tau mutants containing a single remaining tyrosine
were more difficult to interpret, given that they closely
resembled the banding pattern of phosphotyrosine for
the TauYAllF mutant, in which no tyrosine residues are
present. Looking at the phosphotyrosine banding pat-
terns it is likely that there was a degree of background
immunoprecipitation of the LckY505F, as the banding
pattern seen in the phosphotyrosine immunoblot of the
transfection with LckY505F alone resembles the pattern
seen in the Tau Y29R, Y197R, Y310R and Y394R trans-
fected samples. Although the results of this experiment
are somewhat ambiguous, when taken together with the
data from the transfections with single Tyr-Phe tau
mutants (Figure 4A), these data suggest that Lck can
phosphorylate multiple sites in tau within cells, and sug-
gested that Tyr18 is a preferred site.
Discussion
Tyrosine-phosphorylated tau has previously been identi-
fied in foetal brain and in PHF-tau from AD brain
[16-18]. Phosphorylation of Tyr18 was identified using
phosphospecific antibodies [19], while phosphorylation
of Tyr197 and Tyr394 was identified using LC-MS/MS
[17,18]. Our current studies are in agreement with pre-
vious reports that in co-transfected cells Fyn phosphory-
lates Tyr18 [17,19] while Abl phosphorylates Tyr394
[17]. Whilst a site-specific antibody [19] identified Tyr18
as a Fyn and Src phosphorylation site in vitro,s u c hs t u -
dies do not exclude the possibility of phosphorylation of
other sites as well.
It has been reported that Lck mRNA is down regu-
lated in AD brain, and more recently the Lck gene has
been implicated as the locus for a possible genetic risk
factor in AD; however, changes in protein expression or
SNPs in Lck have not been fully characterised [36,37].
Although it might be expected that Lck phosphorylates
tau in a manner similar to the other Src-family kinases
Fyn and Src, the structural differences between these
kinases might result in different substrate specificities.
Therefore we undertook a study of tau phosphorylation
by Lck to investigate this.
Phosphorylation of recombinant tau in vitro with Lck
or Fyn shows that they are both able to phosphorylate
several, possibly all, of the five tyrosines. However
Tyr18, already known to be the favoured site for Fyn,
S r ca n dS y k ,i sa l s oas i t ef a v o u r e db yL c k .T h i si sc o n -
sistent with our results showing that when activated Lck
(LckY505F) was co-transfected with tau constructs with
only one tyrosine remaining, Tyr18 could be phosphory-
lated better than the other four tyrosines.
Using CHO cells co-transfected with Lck and tau, our
results here indeed show that this kinase differs from
Fyn [17] and Syk [20] in its ability to phosphorylate spe-
cific residues of tau. Wild-type human tau is phosphory-
lated in cells on tyrosine in a Lck-dependent manner,
but this phosphorylation is considerably reduced by
replacing any of the five tyrosines in human tau with
phenylalanine. This is in contrast to earlier results with
Fyn, Syk and Abl and it is unusual for replacement of
tyrosine with phenylalanine to have a global effect on
phosphorylation beyond what would be expected from
removal of a phosphorylation site.
There are several possible reasons for the co-ordinated
inhibition of phosphorylation at several different sites by
mutation of one of them: 1. Conformational changes in
tau structure caused by any one Tyr-to-Phe mutation;
however this is unlikely as tau is a predominantly
unstructured protein [39], and the tyrosines are distribu-
ted throughout the molecule. Nevertheless this is not
entirely unprecedented: Src-family kinases have SH3
domains which can bind to tau [40-42], and Src-SH3
and Fyn-SH3 show some distinct differences in binding
to various forms of tau that are hard to explain except
by invoking conformational differences in tau [41]. 2.
Lck may bind to phenylalanine (perhaps regarding that
sequence as a pseudosubstrate) and so be inhibited.
However, there is no evidence for this. 3. The Tyr-Phe
mutations may alter phosphorylation on serines and
threonines. There is little precedent for this: tyrosines
197 and 394 are in or near regions highly susceptible to
multiple serine/threonine phosphorylation, but tyrosines
18, 29 and 310 are not. However, if altered Ser/Thr
phosphorylation (e.g. at the sites, near Tyr197 and
Tyr394 respectively) reduced the interaction of tau with
Lck, then reduced phosphorylation at all five tyrosines
might be expected.
The in vitro phosphorylation experiments had shown
that Lck and Fyn phosphorylated tau in a similar man-
ner. Lck appeared to be somewhat less selective than
Fyn (or Syk) for Tyr18, but this would not account for
the degree of difference seen in cells. The differences
b e t w e e nt h ek i n a s e ss e e ni nt r a n s f e c t i o ne x p e r i m e n t s ,
therefore, may be due to differences in the behaviour of
these kinases in cells. It is possible that other cellular
proteins may bind to kinases or tau in a kinase-specific
manner, affecting kinase action; there is a precedent for
this, as 14-3-3 protein can bind to both GSK-3b and
tau, affecting the latter’s phosphorylation [43]. When
considering differing substrate phosphorylation in cells
it is also important to consider the cellular localisation
of the kinases; for instance in neurons derived from
embryonic stem cells Fyn and Src, have been show to
be localised to cell bodies and neurites whereas Lck is
localised solely to the cell body [44].
The sequence of tau is highly conserved in mamma-
lian species in the C-terminal half of the molecule that
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more variation in the N-terminal half. Indeed, while
humans and rhesus monkeys have two N-terminal tyr-
osines (18 and 29), other mammalian species (mouse,
rat, cow and goat) have a 10 or 11 amino acid deletion
in this region that includes one of the tyrosines [45],
with the result that the remaining tyrosine is in a
sequence context with features of both primate Tyr18
(on its N-terminal side) and primate Tyr29 (on its
C-terminal side). Its ability to be phosphorylated in
mouse brain as well as in human brain [19] suggests
that Tyr18, rather than Tyr29, may be functionally the
more important. Functions of the N-terminal part of
tau, which has been termed the projection domain,
h a v en o tb e e ne x t e n s i v e l ys t u d i e d ,b u ti ti sr e p o r t e dt o
bind to membranes [46] and to other proteins includ-
ing GSK-3b [47].
The serine/threonine phosphorylation sites on tau are
predominantly in the central part of the molecule or
near the C-terminus, on either side of the microtubule-
binding repeats [3], and phosphorylation inhibits its
binding to microtubules. Phosphorylation of Tyr18 does
not directly affect the ability of tau to bind to microtu-
bules [19], and may therefore have an alternative or
additional role, e.g. in mediating or modulating the
actions of the N-terminal projection domain. This role
may be significant in brain development, as phosphory-
lation of Tyr18 was found in foetal but not in adult
mouse brain [19]. The presence of phosphorylated
Tyr18 [19], Tyr197 [18] and Tyr394 [17] in PHF-tau
from AD brains but apparently not in normal adult
brains suggests the possibility of a role in pathogenesis,
paralleling that of serine/threonine hyperphosphoryla-
tion [48]. This is further indicated in the JNPL3 mouse
model, where tau tyrosine phosphorylation increases
with age of the animals and correlates with the develop-
ment of tau aggregates [18].
It is not yet understood how the reported risk asso-
ciated with the Lck gene locus or the down regulation
of Lck mRNA impact on Lck activity. As the Src-family
kinases appear to have broadly overlapping specificities
for particular tyrosine residues on tau it is possible that
localisation of the Src-family kinase is the determining
factor for phosphorylation rather than their specificity
for different tyrosine residues. It is possible that the
loss of Lck-tau interactions and a concurrent increase
in Fyn-tau interactions may result in tyrosine phos-
phorylation that may favour the development of AD
pathology. This is in keeping with previous reports
describing Fyn-tau interactions altering tau’s cellular
location [34,49] and could in some way explain the
increased phosphorylation of Tyr197 and Tyr394
observed in AD brain. Much further work is needed to
clarify these issues.
Conclusions
By a combination approach of mass spectrometry and
2D phosphopeptide mapping four of the five tyrosines
in tau (Tyr18, Tyr197, Tyr310 and Tyr394) were posi-
tively identified as in vitro Lck phosphorylation sites and
the fifth (Tyr29) was identified as a probable Lck phos-
phorylation site. Two tyrosines (Tyr18 and Tyr197)
were positively identified as in vitro Fyn phosphorylation
sites and Tyr29, Tyr310, Tyr394 as probable phosphory-
lation sites. In co-transfection studies in cells, Lck
showed no preferential for phosphorylation of any of
the five tyrosines over one another, with all tyrosines
appearing to be phosphorylated. This is in contrast to
similar studies using Fyn, Syk or Abl and may be indica-
tive of a differing role for Lck in AD pathogenesis.
Methods
Materials
Human 2N4R tau and 0N3R tau constructs were
donated by M. Goedert (MRC Laboratory of Molecular
Biology, Cambridge, UK). Tau N-terminal and C-
terminal constructs were donated by H. Yanagawa (Mit-
subishi Kasei Institute of Life Sciences, Tokyo, Japan).
2N4R tau, 0N3R tau and tau N- and C-terminal con-
structs were expressed in Escherichia coli and purified
as previously described [50], with the exception that for
2N4R and 0N3R tau the final Mono S chromatography
was omitted. The tau constructs used in this study are
shown in Figure.1. For mammalian expression, V5His-
tagged 2N4R tau in pcDNA3.1 was used, with Tyr-Phe
mutants prepared by site-directed mutagenesis as
described previously [17].
Lck and Fyn proteins were expressed in Sf9 cells using
baculovirus constructs. The Lck construct had a
C-terminal His-tag, while the Fyn construct (a gift from
D. Markby, Sugen, San Francisco, CA, USA) was wild-
type. Lck protein was purified using a cobalt containing
matrix (Talon, Clontech, Palo Alto, CA, USA) and Fyn
by an immunoaffinity column using Fyn3 antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) with
elution by its cognate peptide. Preliminary experiments
were carried out using commercial preparations of Fyn
and Src (Millipore, MA, USA). Lck constructs for mam-
malian expression (both wild-type and activated by
t h eY 5 0 5 Fm u t a t i o n )i nt h ev e c t o rp C Iw e r eag i f tf r o m
M. Bijlmakers (King’s College London) [51].
Trypsin used was Sequencing Grade Modified Trypsin
(Promega, Southampton, UK).C o o m a s s i eB l u es t a i n i n g
of polyacrylamide gels was carried out using Brilliant
B l u eG( S i g m a ,G i l l i n g h a m ,U K ) .2 DP h o s p h o p e p t i d e
mapping was carried out on 20 × 20 cm cellulose coated
plates (Merck VWR, Poole, Dorset, UK). The anti-tau
antibodies used were TP70 which has been described
previously [52], and rabbit anti-human tau from DAKO
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photyrosine antibody 4G10 was obtained from Upstate,
and anti-V5 monoclonal antibody was obtained from
Invitrogen (Paisley, UK). Monoclonal anti-Lck antibody
3 A 5( s c - 4 3 3 )w a so b t a i n e df r o mS a n t aC r u z .O t h e r
reagents for cell culture and immunoprecipitation were
as described previously [17].
In vitro phosphorylation of tau
Phosphorylation was carried out in a volume of 20 μl,
which included 5 μl of tau solution (containing 5 μgo f
tau), 5 μl of Lck or Fyn preparation and 10 μlo fo t h e r
components, to give a final concentration of 50 μM
ATP, 3 μCi [g
32P]ATP if required, 20 mM MgCl2,
5m MM n C l 2, 0.1 mM EDTA, 1 mM DTT and 50 mM
Tris-HCl pH 7.5. The phosphorylation mixture was
incubated for 3 hours at 30°C. Following incubation the
samples were placed in a boiling water bath for 5 min
and then placed on ice for 10 min. After centrifuging at
16,000 × g for 5 min to remove precipitated protein,
10 μl SDS-PAGE sample buffer was added to the super-
natants, which were boiled for a further 5 min and
re-centrifuged before loading onto the gel.
2D Phosphopeptide mapping
Tau (2 μg) that had been tyrosine phosphorylated by
Lck or Fyn was resolved by electrophoresis on 10% poly-
acrylamide gels and then transferred by semi-dry blot-
ting onto Immobilon P (PVDF) membrane (Millipore,
Watford, UK) at 15 V for 45 min. Protein was visualised
initially by staining the membrane with 0.1% (wt/vol)
amido black solution and the radiolabelled protein
bands were located using a Fuji FUJIX BAS 1000 ima-
ging system. The phosphorylated tau bands were cut
out and counted using Cerenkov radiation. 2D Phospho-
peptide mapping was carried out as described by Boyle
et al [53]. Briefly, the excised bands were washed twice
in 200 μM NaOH, then blocked in 0.5% (vol/vol) polyvi-
nylpyrrolidine in 0.1 M acetic acid for 1 hour at 37°C,
followed by five brief washes in H2O. Trypsin (1 μg) in
10 μl 0.2 M ammonium bicarbonate (pH 8.0) was added
to the membrane strips. After trypsin treatment for 8
hours at 37°C a further 10 μl( 1μg) of trypsin solution
was added and the strips were incubated for an addi-
tional 4 hours at 37°C. The surrounding liquid was then
removed to a fresh tube and counted by Cerenkov
radiation. Water (400 μl) was added to the samples
which were then dried by vacuum centrifugation
(Speed-Vac). The drying was repeated with 1 ml of H2O
and then twice with 400 μl of pH 1.9 electrophoresis
buffer (2.8% vol/vol formic acid, 7.8% vol/vol glacial
acetic acid, 89.4% vol/vol H2O). The samples were
dissolved in 10 μl of pH 1.9 electrophoresis buffer
and loaded onto cellulose coated glass plates (20 cm ×
20 cm). In the first dimension peptides were separated
by electrophoresis at pH 1.9 at 1 kV for 1.25 hours. The
second dimension consisted of chromatography in phos-
pho-chromatography buffer (37.5% vol/vol n-butanol,
25% vol/vol pyridine, 7.5% vol/vol glacial acetic acid,
30% vol/vol H2O) for 18-20 hours. The maps were then
visualised by imaging or autoradiography.
Phosphoamino acid analysis
The required spots were scraped from the cellulose
coated glass plates and 200 μl of 20% (vol/vol) acetoni-
trile was added to each sample of cellulose powder. The
samples were mixed thoroughly, placed in a sonicating
bath for 10 minutes, and centrifuged at 16,000 × g for
5 min. The supernatants were removed to fresh tubes
and the process was repeated, and the second superna-
tants were pooled with the first. The samples were dried
by vacuum centrifugation (Speed-Vac), dissolved in
100 μl of 6M HCl and hydrolysed for 1 hour at 110°C.
The samples were again dried in the Speed-Vac,
counted using Cerenkov radiation and dissolved in 5 μl
of pH 1.9 electrophoresis buffer. 2 μlo fp h o s p h o a m i n o
acid standards (0.3 mg/ml each of phosphoserine, phos-
phothreonine and phosphotyrosine in water) was added.
The samples were loaded onto cellulose coated glass
plates (4 samples per plate) and separated in the first
dimension by electrophoresis at pH 1.9 at 1 kV for
40 min and in the second dimension by electrophoresis
at pH 3.5 (using pH 3.5 buffer which consisted of 5%
(vol/vol) glacial acetic acid, 0.5% (vol/vol) pyridine,
94.5% (vol/vol) H2O) at 1 kV for 25 min [53]. The plates
were sprayed with 0.25% (wt/vol) ninhydrin in acetone
a n dp l a c e di na no v e na t1 6 0 ° Cf o r1m i nt or e v e a lt h e
position of the amino acid standards. The positions of
the radiolabelled amino acids were visualised by imaging
and compared to the positions of the non-radioactive
standards.
Analysis of tau peptides by mass spectrometry
Samples of tyrosine phosphorylated tau (phosphorylated
either by Lck or Fyn) as well as unphosphorylated tau
were resolved by SDS-PAGE and stained with Coomas-
sie Brilliant Blue G, and the required band was cut out
of the gel.
For MALDI-ToF MS (matrix assisted laser desorption/
ionisation time of flight mass spectrometry) analysis,
cysteine residues were reduced with 10 mM DTT in
100 mM ammonium bicarbonate (56°C for 30 min) and
derivatised by treatment with 55 mM iodoacetamide
(room temperature for 20 min) to form stable carbami-
domethyl derivatives. Trypsin digestion was carried out
o v e r n i g h ta tr o o mt e m p e r a t u r ea f t e ra ni n i t i a l1h o u r
incubation at 37°C. The digested samples were desalted
and concentrated using ZipTipC18 microtips (Millipore,
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(vol/vol) acetonitrile/0.1% (wt/vol) trifluoroacetic acid,
and 0.5 μl was loaded onto a target plate with 0.5 μl
matrix (a-cyano-4-hydroxy-cinnamic acid). Peptide mass
fingerprints were acquiredi np o s i t i v ei o nm o d ea n d
reflectron mode with delayed extraction on a Voyager
DE-Pro instrument (Applied Biosystems, Foster City,
CA, USA). An autolytic tryptic peptide of mass
2163.0569 Da was used as an internal mass standard,
resulting in a mass accuracy <50 ppm.
For LC-MS/MS (liquid chromatography tandem mass
spectrometry) analysis, samples were prepared as
described above for MALDI-ToF MS, and peptides were
then extracted from SDS-PAGE gel pieces by incubating
with 50 mM ammonium bicarbonate at 37° for 15 min
followed by acetonitrile for 15 min, and repeating this
cycle once. The extracts were pooled and dried in a
Speed-Vac. Each sample was then resuspended in 23 μl
of 50 mM ammonium bicarbonate and analysed. Chro-
matographic separations were performed using an Ulti-
mate LC system (Dionex, Camberley, UK). Peptides
were resolved by reverse phase chromatography on a
75 μm C18 PepMap column (Dionex). A gradient of
acetonitrile in 0.05% (vol/vol) formic acid was delivered
to elute the peptides at a flow rate of 200 nl/min. Pep-
tides were ionised by electrospray ionisation using a Z-
spray source fitted to a QToF-micro mass spectrometer
(Waters Ltd, Elstree, UK). The instrument was set to
run in automated switch mode, selecting precursor ions
based on their intensity and charge, for sequencing by
collision-induced fragmentation. The MS/MS analyses
were conducted using collision energy profiles that were
chosen based on the m/z and the charge state of the
peptide; a total of nine individual MS/MS spectra were
combined for each precursor.
The mass spectral data were processed into peptide
mass lists (MALDI-ToF MS data) and peak lists (MS/MS
data) and searched against the full length sequence of
human tau using Mascot software (Matrix Science,
London, UK). Tyrosine phosphorylated peptides were
identified by selecting this as a variable modification
within the searching parameters. Serine and threonine
phosphorylation was also included in the search. The
exact location of the modification within each peptide was
determined by the pattern of fragment ions produced.
Analysis of phosphopeptide spots from 2D maps by mass
spectrometry
Major spots were identified by imaging of radioactivity
and the area corresponding to the spot on the cellulose
was scraped from the plate. Peptides were extracted
from the cellulose using 50% (vol/vol) MeOH and 0.05%
(vol/vol) formic acid in water, and then dried in a
Speed-Vac. The samples were then analysed by MALDI-
ToF and LC-MS/MS as detailed above.
Transfection and harvesting of fibroblasts,
immunoprecipitations and Western blotting
Culturing, transfection and harvesting of COS-7 cells
was carried out as described previously [17]. Cells were
harvested 24 h after transfection into SDS-PAGE sample
buffer [54], and immunoprecipitations and Western ana-
lysis were carried out as described previously [17,55].
After visualisation of blots using enhanced chemilumi-
nescence, films were scanned using an Epson Perfection
4990 scanner (Hemel Hempstead, UK) and quantified
using Phoretix 1D Plus software (Nonlinear Dynamics,
Newcastle upon Tyne, UK).
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